# BIBW 2992 (Afatinib) and Vinorelbine

> **NCT01531764** · PHASE2 · TERMINATED · sponsor: **University of Magdeburg** · enrollment: 2 (actual)

## Conditions studied

- Carcinoma Breast Stage IV

## Interventions

- **DRUG:** BIBW 2992 in combination with vinorelbine

## Key facts

- **NCT ID:** NCT01531764
- **Lead sponsor:** University of Magdeburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The recruitment was discontinued because of failure to meet expected enrolment goals
- **Last updated:** 2013-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531764, "BIBW 2992 (Afatinib) and Vinorelbine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01531764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*